Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 264

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1B
Chunk 264
---
 company as a professional technology
services company, resulting in the successful sale of the company to British Telecom. From October 1995 through April 1998, Mr.
Rudelius was a founding Managing Partner of AT&T Solutions, Inc., a subsidiary of AT&T Inc. (NYSE: T), and headed the
Media, Entertainment & Communications industry practice. From January 1990 through September 1995, Mr. Rudelius was a partner in
McKinsey & Company’s information, technology, and systems practice, during which time he headed the practice in Japan and
the United Kingdom. Mr. Rudelius began his career at Arthur Andersen & Co. where he was a leader in the firm’s financial
accounting systems consulting practice. Mr. Rudelius served as a member of the Axogen, Inc. (NASDAQ: AXGN) Board of Directors for
ten years from September 2010 through September 30, 2020, where he served as chairman of the audit committee and as a member of the compensation
committee. Mr. Rudelius has an M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. in mathematics and
economics from Gustavus Adolphus College in St. Peter, Minnesota. Mr. Rudelius’ qualifications to serve on our Board of
Directors include his extensive executive leadership and financial experience, particularly in connection with rapid growth
technology businesses, and his experience as a director of publicly traded companies.

Michael
Eldred. Mr. Eldred previously served as president and CEO of North American Operations at Dechra Pharmaceutical. He joined Dechra
in 2004 and was responsible for Dechra Veterinary Products’ North American business until departing in June 2024. He was Dechra’s
first employee in the U.S., where he built the U.S., Mexican and Canadian teams to more than 250 people and helped grow sales to £191.6
million. He was also involved in more than 15 commercial agreements and acquisitions for Dechra, including Pharmaderm, DermaPet, Phycox
Animal Health and Putney. Prior to Dechra, he served as director of Business Development and Corporate Business Unit at Virbac Corporation,
an animal health pharmaceutical company. At Virbac, he directed and coordinated all acquisition, divestiture, licensing agreements, and
business alliances strategic to the company. He was involved with such acquisitions as King Pharmaceutical’s animal